Cytotoxicity of cyclometallated ruthenium complexes: The role of ligand exchange on the activity

Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences

Volumn 371, Issue 1995, 2013, Pages

  Palmer, Alycia M ^a   Peña, Bruno ^b   Sears, R Bryan ^c   Chen, Olivia ^a   El Ojaimi, Maya ^d   Thummel, Randolph R ^d   Dunbar, Kim R ^b   Turro, Claudia ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c EMMANUEL COLLEGE   (United States)

^d University of Houston   (United States)

Author keywords

Glutathione; Ligand exchange; Photochemistry; Photodynamic therapy; Ruthenium

Indexed keywords

BIOMOLECULES; CELL DEATH; CHARGE TRANSFER; LIGANDS; PEPTIDES; PHOTOCHEMICAL REACTIONS; PHOTODYNAMIC THERAPY; RUTHENIUM COMPOUNDS; TISSUE;

1 ,10-PHENANTHROLINE; COORDINATION SPHERE; GLUTATHIONES; LIGAND EXCHANGES; LIGAND SUBSTITUTION; METAL-TO-LIGAND CHARGE TRANSFER; RUTHENIUM COMPLEXES; TISSUE PENETRATIONS;

RUTHENIUM;

GLUTATHIONE; RUTHENIUM;

ARTICLE; CELL SURVIVAL; DRUG EFFECT; FEMALE; HUMAN; LIGAND EXCHANGE; LIGHT; METHODOLOGY; OVARY TUMOR; PATHOLOGY; PHOTOCHEMISTRY; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; TREATMENT OUTCOME; TUMOR CELL LINE;

GLUTATHIONE; LIGAND EXCHANGE; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; RUTHENIUM;

CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; LIGHT; OVARIAN NEOPLASMS; PHOTOCHEMOTHERAPY; RUTHENIUM; TREATMENT OUTCOME;

EID: 84887384864     PISSN: 1364503X     EISSN: None     Source Type: Journal    
DOI: 10.1098/rsta.2012.0135     Document Type: Article

References (47)

1. Nyst HJ, Tan IB, Stewart FA, Balm AJM. 2006 Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer Photodiag. Photodyn. Ther. 6, 3-11. (doi:10.1016/j.pdpdt.2009.03.002)
2. Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S. 2008 Photodynamic therapy of cancer. Basic principles and applications. Clin. Trans. Oncol. 10, 148-154. (doi:10.1007/s12094-008-0172-2)
3. O'Connor AE, Gallagher WM, Byrne AT. 2009 Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem. Photobiol. 85, 1053-1074. (doi:10.1111/j.1751-1097.2009. 00585.x)
4. Gray J, Fullarton G. 2007 The current role of photodynamic therapy in esophageal dysplasia and cancer. Photodiag. Photodyn. Ther. 4, 151-159. (doi:10.1016/j.pdpdt.2007.04.003) (Pubitemid 47239505)
5. Allison RR, Cuenca R, Downie GH, Randall ME, Bagnato VS, Sibata CH. 2005 PD/PDT for gynecological disease: a clinical review. Photodiag. Photodyn. Ther. 2, 51-63. (doi:10.1016/s1572-1000(05)00033-5) (Pubitemid 40805373)
6. Svanberg K, Bendsoe N, Axelsson J, Andersson-Engels S, Svanberg S. 2010 Photodynamic therapy: superficial and interstitial illumination. J. Biomed. Optics 15, 041502. (doi:10.1117/1.3466579)
7. Zuluaga M-F, Lange N. 2008 Combination of photodynamic therapy with anti-cancer agents. Curr. Med. Chem. 15, 1655-1673. (doi:10.2174/ 092986708784872401)
8. Moghissi K, Dixon K, StringerM, Thorpe JAC. 2009 Photofrin PDT for early stage oesophageal cancer: long term results in 40 patients and literature review. Photodiag. Photodyn. Ther. 6, 159-166. (doi:10.1016/j/pdpdt.2009.07.026)
9. Schatzschneider U. 2010 Photoactivated biological activity of transition-metal complexes. Eur. J. Inorg. Chem. 10, 1451-1467. (doi:10.1002/ejic.201000003)
10. Farrer NJ, Salassa L, Sadler PJ. 2009 Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine. Dalton Trans. 48, 10 690-10 701. (doi:10.1039/b917753a)
11. Singh T, Turro C. 2004 Photoinduced DNA binding by cis-[Ru(bpy)2(NH3)2] 2+. Inorg. Chem. 43, 7260-7262. (doi:10.1021/ic049075k)
12. Garner R, Gallucci J, Dunbar KR, Turro C. 2011 [Ru(bpy)2(5-cyanouracil)2] 2+ as a potential light-activated dual-action therapeutic agent. Inorg. Chem. 50, 9213-9215. (doi:10.1021/ic201615u)
13. Respondek T, Garner RN, Herroon MK, Podgorski I, Turro C, Kodanko JJ. 2011 Light activation of a cysteine protease inhibitor: caging of a peptidomimetic nitrile with RuII(bpy)2. J. Am. Chem. Soc. 133, 17 164-17 167. (doi:10.1021/ja208084s)
14. Respondek T, Herroon MK, Garner RN, Turro C, Podgorski I, Kodanko JJ. Submitted. Targeting intracellular proteolysis with a light-activated cathepsin K inhibitor.
15. Wang D, Lippard SJ. 2005 Cellular processing of platinum cancer drugs. Nat. Rev. Drug Disc. 4, 307-320. (doi:10.1038/nrd1691) (Pubitemid 41130944)
16. Momekov G, Bakalova A, Karaivanova M. 2005 Novel approaches towards development of non-classical platinum-based antineoplastic agents: design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity. Curr. Med. Chem. 12, 2177-2191. (doi:10.2174/0929867054864877) (Pubitemid 41179706)
17. Jamieson ER, Lippard SJ. 1999 Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467-2498. (doi:10.1021/cr980421n)
18. Fuertes MA, Alonso C, Perez JM. 2003 Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103, 645-662. (doi:10.1021/cr020010d)
19. Berners-Price SJ, Appleton TG. 2000 The chemistry of cisplatin in aqueous solution. In Platinum-based drugs in cancer therapy (eds LR Kelland, NP Farrell), pp. 3-31. Tutowa, NJ: Humana Press.
20. Lutterman DA, Fu PK, Turro C. 2006 Cis-[Rh2(ì-O2CCH3)2(CH3CN)6]2+ as a photoactivated cisplatin analog. J. Am. Chem. Soc. Commun. 128, 738-739. (doi:10.1021/ja057620q) (Pubitemid 43153023)
21. Zhao R, Hammitt R, Thummel RP, Liu Y, Turro C, Snapka RM. 2009 Nuclear targets of photodynamic tridentate ruthenium complexes. Dalton Trans. 48, 10 926-10 931. (doi:10.1039/b913959a)
22. Antonarakis ES, Emadi A. 2010 Ruthenium-based chemotherapeutics: are they ready for prime time Cancer Chemother. Pharmacol. 66, 1-9. (doi:10.1007/s00280- 010-1293-1)
23. Habtemariam A et al. 2006 Structure-activity relationships of cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J. Med. Chem. 49, 6858-6868. (doi:10.1021/jm060596m) (Pubitemid 44749753)
24. Liu HK, Berners-Price SJ, Wang FY, Parkinson JA, Xu JJ, Bella J, Sadler PJ. 2006 Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex. Angew. Chem. Int. Ed. 45, 8153-8156. (doi:10.1002/anie.200602873) (Pubitemid 44974150)
25. Yan YK, Melchart M, Habtemariam A, Sadler PJ. 2005 Organometallic chemistry, biology, and medicine: ruthenium arene anticancer complexes. Chem. Commun. 38, 4764-4777. (doi:10.1039/b508531b) (Pubitemid 41509143)
26. Ang WH, Dyson PJ. 2006 Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem. 20, 4003-4018. (doi:10.1002/ejic. 200600723)
27. Novakova O, Hofr C, Brabec V. 2000 Modification of natural, double-helical DNA by antitumor cis-and trans-[Cl2(Me2SO)4Ru] in cell-free media. Biochem. Pharmacol. 60, 1761-1771. (doi:10.1016/S0006-2952(00)00495-0)
28. Malina J, Novakova O, Keppler BK, Alessio E, Brabec V. 2001 Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cellfree media. J. Biol. Inorg. Chem. 6, 435-445. (doi:10.1007/S007750100223) (Pubitemid 32822134)
29. Novakova O, Chen H, Vrana O, Rodger A, Sadler PJ, Brabec V. 2003 DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry 42, 11 544-11 554. (doi:10.1021/bi034933u) (Pubitemid 37205749)
30. Hotze ACG, Bacac M, Velders AH, Jansen BAJ, Kooijman H, Spek AL, Haasnoot JG, Reedijk J. 2003 New cytotoxic and water-soluble bis(2-phenylazopyridine) ruthenium(II) complexes. J. Med. Chem. 46, 1743-1750. (doi:10.1021/jm021110e) (Pubitemid 36444226)
31. Puim D, van Waardenburg RC, Beijnen JH, Schellens JH. 2004 Cytotoxicity of the organic ruthenium anticancer drug NAMI-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother. Pharmacol. 54, 71-78. (doi:10.1007/s00280-004-0773-6) (Pubitemid 38858368)
32. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. 2006 From bench to bedside: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III) ] (KP1019 or FFC14A). J. Inorg. Biochem. 100, 891-904. (doi:10.1016/j.jinorgbio. 2006.02.013) (Pubitemid 44308176)
33. Bomben PG, Robson KCD, Sedach PA, Berlinguette CP. 2009 On the viability of cyclometalated Ru(II) complexes for light-harvesting applications. Inorg. Chem. 48, 9631-9643. (doi:10.1021/ic900653q)
34. Gaiddon C, Jeannequin P, Bischoff P, Pfeffer M, Sirlin C, Loeffler JP. 2005 Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J. Pharmacol. Exp. Ther. 315, 1403-1411. (doi:10.1124/jpet.105.089342) (Pubitemid 41635431)
35. Leyva L et al. 2007 Synthesis of cycloruthenated compounds as potential anticancer agents. Eur. J. Inorg. Chem. 19, 3055-3066. (doi:10.1002/ejic. 200601149)
36. Fedorova TV, Vilesov AS, Kurzeev SA, Stepanova EV, Landesman EO, Koroleva OV. 2006 Development of a novel enzyme-redox-mediator system based on a fungal laccase and ruthenium complexes. Appl. Biochem.Microbiol. 42, 550-557. (doi:10.1134/S0003683806060044) (Pubitemid 44663317)
37. Ryabov AD et al. 2005 Synthesis, characterization, and electrochemistry of biorelevant photosensitive low-potential orthometalated ruthenium complexes. Inorg. Chem. 44, 1626-1634. (doi:10.1021/ic048270w) (Pubitemid 40333485)
38. Fernandez S, Pfeffer M, Ritleng V, Sirlin C. 1999 An effective route to cycloruthenated N-ligands under mild conditions. Organometallics 18, 2390-2394. (doi:10.1021/om9901067) (Pubitemid 129674760)
39. Juris A, Balzani V, Barigelletti F, Campagna S, Belser P, von Zelewsky A. 1988 Ru(II) polypiridine complexes: photophysics, photochemistry, electrochemistry, and chemiluminescence. Coord. Chem. Rev. 84, 85-277. (doi:10.1016/0010-8545(88)80032-8)
40. Peña B, Leed NA, Dunbar KR, Turro C. 2012 Excited state dynamics of two new Ru(II) cyclometallated dyes: relation to cells for solar energy conversion and comparison to conventional systems. J. Phys. Chem. C 116, 22 186-22 195. (doi:10.1021/jp306352f)
41. Ryabov AD, Estevez H, Alexandrova L, Pfeffer M, Le Lagadec R. 2006 Unusual phenomenon in the chemistry of orthometalated ruthenium (II) complexes. Inorg. Chim. Acta 359, 883-887. (doi:10.1016/j.jca.2005.05.034)
42. Pinnick DV, Durham B. 1984 Photosubstitution reactions of Ru(bpy)2XYn+ complexes. Inorg. Chem. 23, 1440-1445. (doi:10.1021/ic00178a028)
43. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson M. 1992 High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl Acad. Sci. USA 89, 3070-3074. (doi:10.1073/pnas.89.7.3070)
44. Lutterman DA, Rachford AA, Rack JJ, Turro C. 2010 Electronic and steric effects on the photoisomerization of dimethylsulfoxide complexes of Ru(II) containing picolinate. J. Phys. Chem. 1, 3371-3375. (doi:10.1021/jz1012966)
45. McClure BA, Rack JJ. 2010 Isomerization in photochromic ruthenium sulfoxide complexes. Eur. J. Inorg. Chem. 25, 3895-3904. (doi:10.1002/ejic. 200900548)
46. Rack JJ, Mockus NV. 2003 Roomerature photochromism in cis-and trans-[Ru(bpy)2(DMSO)2]2+. Inorg. Chem. 42, 5792-5794. (doi:10.1021/ic0345323)
47. Svardal AM, Mansoor MA, Ueland PM. 1990 Determination of reduced, oxidized, and protein-bound glutathione in human plasma and human precolumn derivatization with monobromobimane and liquid chromatography. Anal. Biochem. 184, 338-346. (doi:10.1016/0003-2697(90)90691-2) (Pubitemid 20055634)